Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 389

1.

Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841.

Krisch I, Bole-Vunduk B, Pepelnak M, Lavric B, Ocvirk A, Budihna MV, Sket D.

J Pharmacol Exp Ther. 1994 Oct;271(1):343-52.

PMID:
7965734
[PubMed - indexed for MEDLINE]
2.

Ergoline derivative LEK-8829-induced turning behavior in rats with unilateral striatal ibotenic acid lesions: interaction with bromocriptine.

Sprah L, Zivin M, Sket D.

J Pharmacol Exp Ther. 1999 Mar;288(3):1093-100.

PMID:
10027846
[PubMed - indexed for MEDLINE]
Free Article
4.

The D1 receptor-mediated effects of the ergoline derivative LEK-8829 in rats with unilateral 6-hydroxydopamine lesions.

Zivin M, Sprah L, Sket D.

Br J Pharmacol. 1996 Nov;119(6):1187-96.

PMID:
8937722
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Antiparkinsonian potential of interaction of LEK-8829 with bromocriptine.

Zivin M, Sprah L, Sket D.

Eur J Pharmacol. 1998 May 22;349(2-3):151-7.

PMID:
9671092
[PubMed - indexed for MEDLINE]
7.

Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.

Oka M, Noda Y, Ochi Y, Furukawa K, Une T, Kurumiya S, Hino K, Karasawa T.

J Pharmacol Exp Ther. 1993 Jan;264(1):158-65.

PMID:
8093723
[PubMed - indexed for MEDLINE]
8.

Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.

Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A.

J Pharmacol Exp Ther. 1988 Dec;247(3):1093-102.

PMID:
2905002
[PubMed - indexed for MEDLINE]
9.

S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol.

Millan MJ, Schreiber R, Dekeyne A, Rivet JM, Bervoets K, Mavridis M, Sebban C, Maurel-Remy S, Newman-Tancredi A, Spedding M, Muller O, Lavielle G, Brocco M.

J Pharmacol Exp Ther. 1998 Sep;286(3):1356-73.

PMID:
9732399
[PubMed - indexed for MEDLINE]
Free Article
10.

Behavioral studies on LEK-8804, a new ergoline derivative with potent 5-HT1A receptor agonist and 5-HT2 receptor antagonist activity.

Krisch I, Bole-Vunduk B.

Pharmacol Biochem Behav. 1994 Feb;47(2):301-5.

PMID:
8146221
[PubMed - indexed for MEDLINE]
11.

Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for sigma receptors.

Takahashi S, Sonehara K, Takagi K, Miwa T, Horikomi K, Mita N, Nagase H, Iizuka K, Sakai K.

Psychopharmacology (Berl). 1999 Aug;145(3):295-302.

PMID:
10494578
[PubMed - indexed for MEDLINE]
12.

Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).

Megens AA, Awouters FH, Meert TF, Schellekens KH, Niemegeers CJ, Janssen PA.

J Pharmacol Exp Ther. 1992 Jan;260(1):146-59.

PMID:
1370538
[PubMed - indexed for MEDLINE]
13.

PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.

Corbin AE, Meltzer LT, Ninteman FW, Wiley JN, Christoffersen CL, Wustrow DJ, Wise LD, Pugsley TA, Heffner TG.

Neuropharmacology. 2000 Apr 27;39(7):1211-21.

PMID:
10760363
[PubMed - indexed for MEDLINE]
14.

In vitro and in vivo pharmacological profile of 4-(4-fluorobenzylidene)-1-[2-[5-(4-fluorophenyl)-1H-pyrazol-4-yl] ethyl] piperidine (NRA0161).

Suzuki Y, Funakoshi T, Chaki S, Kawashima N, Ogawa S, Kumagai T, Nakazato A, Komurasaki T, Okuyama S.

Life Sci. 2002 Oct 18;71(22):2603-15.

PMID:
12354579
[PubMed - indexed for MEDLINE]
15.

Similar pharmacological properties of 8-OH-DPAT and alnespirone (S 20499) at dopamine receptors: comparison with buspirone.

Protais P, Lesourd M, Comoy E.

Eur J Pharmacol. 1998 Jul 10;352(2-3):179-87.

PMID:
9716353
[PubMed - indexed for MEDLINE]
16.

Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.

Schotte A, Janssen PF, Megens AA, Leysen JE.

Brain Res. 1993 Dec 24;631(2):191-202.

PMID:
7510574
[PubMed - indexed for MEDLINE]
17.

KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.

Park WK, Jeong D, Cho H, Lee SJ, Cha MY, Pae AN, Choi KI, Koh HY, Kong JY.

Pharmacol Biochem Behav. 2005 Oct;82(2):361-72. Epub 2005 Oct 10.

PMID:
16216322
[PubMed - indexed for MEDLINE]
18.

New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.

Liao Y, Venhuis BJ, Rodenhuis N, Timmerman W, Wikström H, Meier E, Bartoszyk GD, Böttcher H, Seyfried CA, Sundell S.

J Med Chem. 1999 Jun 17;42(12):2235-44.

PMID:
10377229
[PubMed - indexed for MEDLINE]
19.

Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions.

Hirose A, Kato T, Ohno Y, Shimizu H, Tanaka H, Nakamura M, Katsube J.

Jpn J Pharmacol. 1990 Jul;53(3):321-9.

PMID:
1975278
[PubMed - indexed for MEDLINE]
Free Article
20.

The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.

Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Kumagai T, Nakazato A, Nagamine M, Yamaguchi K, Tomisawa K.

Br J Pharmacol. 1997 Jun;121(3):515-25.

PMID:
9179395
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk